What's Happening?
Nexalin Technology, Inc. has announced significant findings from a study published in BMC Psychiatry, highlighting the effectiveness of its Deep Intracranial Frequency Stimulation (DIFS) technology. The study focused on six female adolescents with non-suicidal
self-injury (NSSI) and reported statistically significant reductions in self-injury behaviors and depressive symptoms following 21 days of 77.5 Hz, 15 mA stimulation. The research also noted changes in brain-network activity and connectivity, providing neurophysiological evidence supporting the non-invasive, high-power DIFS technology. This study adds to Nexalin's growing body of research across various mental health conditions, including insomnia, depression, traumatic brain injury, PTSD, Alzheimer's disease, and ADHD.
Why It's Important?
The findings from this study are significant as they offer a potential non-invasive, drug-free treatment option for adolescents struggling with self-injury and depression. The use of DIFS technology could revolutionize the approach to mental health treatment by targeting dysfunctional brain activity and connectivity, rather than relying solely on subjective symptom reporting. This could lead to broader acceptance and application of Nexalin's technology across multiple mental health disorders, providing a safer alternative to traditional treatments. The study's results could influence future research and clinical practices, potentially improving outcomes for patients with treatment-resistant mental health conditions.
What's Next?
Nexalin plans to continue its research efforts, aiming to validate these preliminary findings in larger, randomized controlled trials. The company is focused on expanding the clinical relevance of its DIFS technology and establishing a robust evidence base to support its efficacy. Future studies will likely explore the technology's application across a wider range of mental health disorders, potentially leading to regulatory approvals and broader market adoption. Nexalin's ongoing research and development efforts could position the company as a leader in non-invasive neurostimulation for mental health treatment.
